Home
Live Updates
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader ... : comparemela.com
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader ...
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML
Related Keywords
Texas ,
United States ,
Boston ,
Massachusetts ,
Watertown ,
American ,
Justine Koenigsberg ,
Jared Gollob ,
Kymera Therapeutics Inc ,
University Of Texas Md Anderson Cancer Center ,
Exchange Commission ,
American Society Of Clinical Oncology ,
Resource Library ,
Nasdaq ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Chief Medical Officer ,
Naval Daver ,
Cancer Center ,
Response Assessments ,
Private Securities Litigation Reform Act ,
Kymera Therapeutics ,
Kymera Therapeutic ,
Annual Report ,
Media Contact ,
comparemela.com © 2020. All Rights Reserved.